Four Cases of Port-Wine Birthmark Treated with Hematoporphyrin Monomethyl Ether-Mediated Photodynamic Therapy After Radioactive Nuclide Patch Therapy.

PDT PWB hematoporphyrin monomethyl ether photodynamic therapy port-wine birthmark radioactive nuclide patch therapy

Journal

Clinical, cosmetic and investigational dermatology
ISSN: 1178-7015
Titre abrégé: Clin Cosmet Investig Dermatol
Pays: New Zealand
ID NLM: 101543449

Informations de publication

Date de publication:
2023
Historique:
received: 26 04 2023
accepted: 22 06 2023
medline: 5 7 2023
pubmed: 5 7 2023
entrez: 5 7 2023
Statut: epublish

Résumé

Port-wine birthmark (PWB) are congenital vascular malformations that commonly occur on the face and neck, with an incidence of 0.3-0.5% in the general population, causing significant negative psychological effects and economic burden to patients. Nevertheless, amidst the plethora of different treatment methods for PWB, choosing the option that best suits the patient's need can be a challenge. In recent years, traditional treatment methods for PWB have been replaced by new therapies, and radioactive nuclide patch therapy is one of them. A panel of experts sought to describe herein 4 clinical cases, illustrating the PDT can demonstrate good precision and efficacy in the treatment of PWB. The research findings show the 4 patients in this group had a history of treatment with radioactive isotope patches. After 2-3 sessions of HMME-PDT, all cases achieved satisfactory results, the color of the red skin lesions significantly faded, and the area of the lesions decreased noticeably. Superficial tissue ultrasound showed a reduction in lesion thickness before and after treatment. In summary, for cases where the efficacy of PWB treatment with radioactive isotope patches is inadequate, Photodynamic therapy (PDT) can be used as a treatment reference.

Identifiants

pubmed: 37404369
doi: 10.2147/CCID.S418019
pii: 418019
pmc: PMC10315137
doi:

Types de publication

Case Reports

Langues

eng

Pagination

1667-1675

Informations de copyright

© 2023 Liu et al.

Déclaration de conflit d'intérêts

The authors have no conflicts of interest to declare in this work.

Références

Front Med (Lausanne). 2023 Feb 21;10:1111234
pubmed: 36895715
J Eur Acad Dermatol Venereol. 2012 Jul;26(7):849-54
pubmed: 21707775
Dermatol Ther (Heidelb). 2022 Jul;12(7):1671-1683
pubmed: 35754066
Photodiagnosis Photodyn Ther. 2014 Dec;11(4):491-7
pubmed: 24973576
Dermatol Ther (Heidelb). 2022 Apr;12(4):861-869
pubmed: 35244881
Biomed Opt Express. 2020 Mar 20;11(4):2122-2136
pubmed: 32341871
Drug Des Devel Ther. 2014 Dec 12;8:2531-8
pubmed: 25548515
Arch Dermatol. 1984 Nov;120(11):1453-5
pubmed: 6497412
Int J Mol Sci. 2022 Oct 12;23(20):
pubmed: 36292993
J Drugs Dermatol. 2021 May 1;20(5):515-518
pubmed: 33938700
PLoS One. 2016 May 26;11(5):e0156219
pubmed: 27227544
Photodiagnosis Photodyn Ther. 2020 Sep;31:101820
pubmed: 32428574
Photodiagnosis Photodyn Ther. 2014 Jun;11(2):134-40
pubmed: 24642191
Lasers Surg Med. 2002;30(1):44-7
pubmed: 11857603

Auteurs

Xu Liu (X)

Department of Dermatology, West China Hospital, Sichuan University, Chengdu, People's Republic of China.

Lihua Yang (L)

Department of Dermatology, West China Hospital, Sichuan University, Chengdu, People's Republic of China.

Qian Zhang (Q)

Department of Dermatology, West China Hospital, Sichuan University, Chengdu, People's Republic of China.

Fengjuan Yang (F)

Department of Dermatology, West China Hospital, Sichuan University, Chengdu, People's Republic of China.

Xian Jiang (X)

Department of Dermatology, West China Hospital, Sichuan University, Chengdu, People's Republic of China.
Laboratory of Dermatology, Clinical Institute of Inflammation and Immunology, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, People's Republic of China.

Classifications MeSH